| P2093 | author name string | Takahiko Kasai | |
| | Akihiro Tamiya | |
| | Kyoichi Okishio | |
| | Naoki Omachi | |
| | Shinji Atagi | |
| | Masaki Kanazu | |
| | Yoshihiko Taniguchi | |
| | Kenji Nakahama | |
| | Yoko Naoki | |
| P2860 | cites work | Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis | Q46154570 |
| | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 |
| | Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. | Q48145064 |
| | Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation | Q48480145 |
| | Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. | Q51652149 |
| | The genetic origin of drug resistance in neoplasms: implications for systemic therapy. | Q52688528 |
| | Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? | Q53060849 |
| | Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. | Q53220080 |
| | High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients | Q79858893 |
| | Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer | Q84582496 |
| | Survival of lung adenocarcinoma patients with malignant pleural effusion | Q87389555 |
| | Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis | Q87559519 |
| | Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies | Q24568071 |
| | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 |
| | Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. | Q27852995 |
| | Global cancer statistics, 2012 | Q27860501 |
| | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 |
| | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 |
| | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 |
| | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 |
| | Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations | Q33419961 |
| | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 |
| | Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 |
| | Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 |
| | The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients | Q34762545 |
| | The molecular biology of brain metastasis | Q35864968 |
| | Crosstalk between cancer cells and bone microenvironment in bone metastasis | Q36032072 |
| | Invader assay for single-nucleotide polymorphism genotyping and gene copy number evaluation | Q36511989 |
| | Cancer to bone: a fatal attraction | Q36884628 |
| | Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs | Q37164590 |
| | The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer | Q37315250 |
| | Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain | Q37968204 |
| | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Q38245038 |
| | Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? | Q38616854 |
| | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial | Q38809376 |
| | Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy | Q41110633 |
| | Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. | Q41452420 |
| | Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). | Q43441821 |
| | Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib | Q43795365 |
| | EGFR mutation and brain metastasis in pulmonary adenocarcinomas | Q45063417 |
| P433 | issue | 6 | |
| P304 | page(s) | 7589-7596 | |
| P577 | publication date | 2017-10-03 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors | |
| P478 | volume | 14 | |